C
Clade Therapeutics
Discovering and delivering next generation cell medicines to improve the lives of patients
About Clade Therapeutics
Clade Therapeutics is a pioneering biotech startup that operates in the healthcare sector, specifically in the field of cell medicine. The company's primary focus is on the discovery and delivery of next-generation cell medicines aimed at improving patient outcomes. Clade's target market includes patients suffering from cancer and autoimmune diseases, two areas where traditional treatment methods often fall short.
Read full description
The company's unique selling proposition lies in its innovative approach to cell medicine. Clade has developed a robust cellular platform that leverages stem-cell derived immune cells for treatment. This platform is built on the company's unparalleled expertise in generating adult human T cells, Treg cells, and B cells from induced pluripotent stem cells (iPSCs). In simple terms, iPSCs are a type of stem cell that can be generated directly from adult cells and have the potential to become any type of cell in the body.
Clade's business model revolves around combining this expertise with its proprietary immune "cloaking" of human iPSCs and their adult derivatives. This, along with novel universal targeting and cellular enhancements, allows the company to develop true "off-the-shelf" cell therapies. These therapies are not only scalable and consistent but also engineerable, making them a leading innovation in the field of cell medicine.
In terms of revenue generation, Clade Therapeutics likely makes money by selling its cell therapies to healthcare providers or directly to patients. The company may also generate income through partnerships with other healthcare companies or through government grants for research and development.
At a glance
- Status
- Acquired
- Founded
- 2020
- Headquarters
- Boston, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 62.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Clade Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2024 | $35M | — | Century Therapeutics | ↗ |
| SERIES AOther financing | Nov 2021 | $87M | $348M | Bristol-Myers Squibb · Emerson Collective · LifeSci Venture Partners · Syncona | — |
Growth signals
Latest recorded traffic for Clade Therapeutics is 760 monthly website visits, up 40.7% over the last three months. Clade Therapeutics's team declined 86.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Bristol-Myers Squibb
Emerson Collective
LifeSci Venture Partners
Syncona
Other known investors3 additional known investors
Century Therapeutics
Harvard University
University of Arizona
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Clade Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clade Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.